title: Rapidly progressive cataract formation associated with non-small-cell lung cancer therapy.
abstract: We report 6 patients who developed rapidly progressive hypermature cataracts after starting treatment with rociletinib, a non-small-cell lung cancer therapy with known side effects of hyperglycemia, fatigue, and prolonged QT. Early cataract detection and surgery may prevent complications during future cataract removal. Although rociletinib development has been suspended, there are patients who have been treated and will continue to be treated with this medication based on their physician's judgment. These physicians should know about the potential for rapid vision loss due to cataracts as a manageable side effect.
  
  
  
  Neither author has a financial or proprietary interest in any material or method mentioned.
authors.affiliation: From the New England Eye Center, Tufts Medical Center, Boston, Massachusetts, USA. Electronic address: eliu1@tuftsmedicalcenter.org.
authors.forename: Erica
authors.initials: E
authors.lastname: Liu
authors.affiliation: From the New England Eye Center, Tufts Medical Center, Boston, Massachusetts, USA.
authors.forename: Kamden
authors.initials: K
authors.lastname: Kopani
mesh_terms: D000178:Acrylamides / Q000009:adverse effects* / Q000627:therapeutic use; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002386:Cataract / Q000139:chemically induced*; D002387:Cataract Extraction; D006801:Humans; D019654:Lens Implantation, Intraocular; D008175:Lung Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000178:Acrylamides; D000970:Antineoplastic Agents; D011743:Pyrimidines; C000589977:rociletinib